AU2013243540C1 - PCV/Mycoplasma hyopneumoniae/PRRS combination vaccine - Google Patents

PCV/Mycoplasma hyopneumoniae/PRRS combination vaccine Download PDF

Info

Publication number
AU2013243540C1
AU2013243540C1 AU2013243540A AU2013243540A AU2013243540C1 AU 2013243540 C1 AU2013243540 C1 AU 2013243540C1 AU 2013243540 A AU2013243540 A AU 2013243540A AU 2013243540 A AU2013243540 A AU 2013243540A AU 2013243540 C1 AU2013243540 C1 AU 2013243540C1
Authority
AU
Australia
Prior art keywords
lys
leu
asn
thr
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013243540A
Other languages
English (en)
Other versions
AU2013243540A1 (en
AU2013243540B2 (en
Inventor
Jeffrey E. Galvin
John Keith GARRETT
James R. Kulawik Ii
Gregory P. Nitzel
Tracy L. RICKER
Megan Marie SMUTZER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48140160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013243540(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of AU2013243540A1 publication Critical patent/AU2013243540A1/en
Assigned to ZOETIS SERVICES LLC reassignment ZOETIS SERVICES LLC Request for Assignment Assignors: ZOETIS LLC
Publication of AU2013243540B2 publication Critical patent/AU2013243540B2/en
Application granted granted Critical
Publication of AU2013243540C1 publication Critical patent/AU2013243540C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2013243540A 2012-04-04 2013-04-03 PCV/Mycoplasma hyopneumoniae/PRRS combination vaccine Ceased AU2013243540C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261620189P 2012-04-04 2012-04-04
US61/620,189 2012-04-04
PCT/US2013/035091 WO2013152086A1 (en) 2012-04-04 2013-04-03 Pcv/mycoplasma hyopneumoniae/prrs combination vaccine

Publications (3)

Publication Number Publication Date
AU2013243540A1 AU2013243540A1 (en) 2014-10-09
AU2013243540B2 AU2013243540B2 (en) 2017-10-19
AU2013243540C1 true AU2013243540C1 (en) 2018-03-01

Family

ID=48140160

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013243540A Ceased AU2013243540C1 (en) 2012-04-04 2013-04-03 PCV/Mycoplasma hyopneumoniae/PRRS combination vaccine

Country Status (32)

Country Link
US (2) US9125886B2 (https=)
EP (2) EP2833909B1 (https=)
JP (1) JP6271504B2 (https=)
KR (1) KR101808903B1 (https=)
AR (1) AR090614A1 (https=)
AU (1) AU2013243540C1 (https=)
BR (1) BR112014024775B1 (https=)
CA (1) CA2869601C (https=)
CL (1) CL2014002676A1 (https=)
CO (1) CO7160027A2 (https=)
CR (1) CR20140438A (https=)
CY (1) CY1121578T1 (https=)
DK (1) DK2833909T3 (https=)
ES (1) ES2719483T3 (https=)
GT (1) GT201400212A (https=)
HR (2) HRP20140956A2 (https=)
HU (1) HUE042405T2 (https=)
LT (1) LT2833909T (https=)
MX (2) MX336502B (https=)
MY (1) MY168549A (https=)
NI (1) NI201400118A (https=)
PH (1) PH12014502252B1 (https=)
PL (1) PL2833909T3 (https=)
PT (1) PT2833909T (https=)
RS (1) RS58480B1 (https=)
RU (1) RU2644256C2 (https=)
SI (1) SI2833909T1 (https=)
TR (1) TR201905176T4 (https=)
TW (1) TWI504406B (https=)
UA (1) UA114504C2 (https=)
WO (1) WO2013152086A1 (https=)
ZA (1) ZA201407133B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027873B8 (en) 2001-07-02 2015-11-11 Zoetis Services LLC One dose vaccination with mycoplasma hyopneumoniae
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
MX361273B (es) 2012-12-28 2018-12-03 Boehringer Ingelheim Vetmedica Gmbh Metodo para obtener una vacuna de mycoplasma.
AU2013370982C9 (en) * 2012-12-28 2019-01-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
US9649370B2 (en) 2013-05-08 2017-05-16 Protatek International, Inc. Vaccine for PCV2 and mycoplasma
BR112016010427B1 (pt) * 2013-11-21 2020-06-02 Agricultural Technology Research Institute Composição para prevenir infecção por mycoplasma spp., vetor de expressão, e método para prepararantígeno solúvel
RU2655615C1 (ru) * 2013-12-03 2018-05-29 Интервет Интернэшнл Б.В. Вакцина для свиней против prrs и lawsonia intracellularis
CN105848675A (zh) * 2013-12-03 2016-08-10 英特维特国际股份有限公司 抗猪圆环病毒2型的疫苗
CN104056265B (zh) * 2014-07-11 2016-04-27 江苏南农高科技股份有限公司 猪圆环病毒2型、猪繁殖与呼吸综合征二联疫苗及其制备方法
WO2016038194A1 (en) * 2014-09-12 2016-03-17 Intervet International B.V. Vaccine for use in protecting a pig against porcine endemic diarrhea virus
CN107073102B (zh) * 2014-09-12 2021-06-25 英特维特国际股份有限公司 用于保护母猪的后代免于猪流行性腹泻病毒的疫苗
BR112017012220A2 (pt) * 2014-12-11 2018-01-30 Intervet Int Bv processos para preparar uma composição de antígeno e uma vacina, composição de antígeno, vacina, usos de uma composição de antígeno e de uma vacina, e, método para prevenção ou redução de infecção por um vírus em suíno e sinais associados à doença.
JP6839714B2 (ja) * 2015-12-28 2021-03-10 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド Ｍ Ｈｙｏ多重ワクチン及びその使用
EP3432920A1 (en) 2016-03-23 2019-01-30 Intervet International B.V. A vaccine for intradermal application against pcv2 and prrs virus infection
JP6907227B2 (ja) * 2016-03-23 2021-07-21 インターベット インターナショナル ベー． フェー． Ｐｃｖ２ウイルス及びマイコプラズマ・ハイオニューモニエ感染症に対する混合ワクチン
JP7009445B2 (ja) * 2016-08-09 2022-02-10 アグリカルチュラル テクノロジー リサーチ インスティテュート マイコプラズマ・ヒオリニス感染を予防治療する組成物
MX2019006992A (es) * 2016-12-14 2019-08-29 Zoetis Services Llc Vacunacion eficaz contra cepas europeas del virus del sindrome reproductivo y respiratorio porcino (prrs) previo al destete.
ES2906854T3 (es) * 2016-12-23 2022-04-20 Intervet Int Bv Vacuna combinada para cerdos
US11311614B2 (en) 2017-04-13 2022-04-26 Intervet Inc. Vaccines containing swine pathogens for associated non-mixed use
CN109280642B (zh) * 2017-07-21 2022-07-22 浙江海隆生物科技有限公司 CHO细胞株及其制备方法和使用该CHO细胞株制备猪圆环病毒2型Cap蛋白及其应用
BR112020011044A2 (pt) 2017-12-04 2020-11-17 Intervet International B.V. vacinação com partículas de replicon e adjuvante de óleo
JP7510874B2 (ja) * 2017-12-22 2024-07-04 ヒプラ シエンティフィック エセ．エレ．ウ． マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン
MX420109B (es) 2018-03-26 2025-02-10 Boehringer Ingelheim Animal Health Usa Inc Metodo para producir una composicion inmunogenica
KR102769557B1 (ko) * 2021-11-19 2025-02-20 주식회사 이노백 신규한 재조합 돼지 써코바이러스 2형 단백질 및 이의 용도
CN119913202B (zh) * 2025-01-15 2025-09-19 北京华夏兴洋生物科技有限公司 用于制备猪三联疫苗的重组载体、重组病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
EP0283840A3 (en) 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
DE3855807T2 (de) 1987-11-03 1997-06-12 Syntex (U.S.A.) Inc., Palo Alto, Calif. Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ZA906806B (en) 1989-08-31 1991-06-26 Ici Australia Operations Plants
ES2112274T5 (es) 1990-05-29 2006-03-01 Wyeth Holdings Corporation Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma.
US6113916A (en) 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
JP3128133B2 (ja) 1991-06-06 2001-01-29 スティッチティング セントラール ディールゲネースクンディグ インスティトゥート 豚の奇病の原因体であるレリスタドエイジェント、それを含むワクチン組成物、豚の奇病の診断キット及び診断方法
US5269315A (en) 1991-08-16 1993-12-14 The Regents Of The University Of California Determining the nature of brain lesions by electroencephalography
DK0601062T4 (da) 1991-08-26 2001-03-14 Univ Minnesota SIRS-vaccine og diagnosefremgangsmåde
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
DK0669971T3 (da) 1991-11-15 2003-04-22 Pfizer Fremgangsmåde til fremstilling af Gram-negative bakterielle vacciner
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
PT968722E (pt) 1994-05-10 2007-09-06 Wyeth Corp Vacina viva melhorada contra brsv.
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
KR100615109B1 (ko) 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
AU1535299A (en) 1997-11-26 1999-06-15 Iowa State University Research Foundation Inc. Recombinant (mycoplasma hyopneumoniae) vaccine
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
CA2290220C (en) 1998-12-22 2013-11-19 Pfizer Products Inc. An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
US6632439B2 (en) 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
CN1612749A (zh) * 2001-07-02 2005-05-04 辉瑞产品公司 用于减弱牲畜体内牛支原体肺炎的猪肺炎支原体疫苗和方法
EP2027873B8 (en) 2001-07-02 2015-11-11 Zoetis Services LLC One dose vaccination with mycoplasma hyopneumoniae
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
EP1546357B1 (en) 2002-06-28 2013-08-07 Iowa State University Research Foundation, Inc. Immunogenic mycoplasma hyopneumoniae polypeptides
SI1651265T1 (sl) 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi
RU2007130801A (ru) 2005-01-13 2009-02-20 Берингер Ингельхайм Ветмедика Гмбх (De) Улучшенные вакцины против репродуктивно-респираторного синдрома свиней (prrs)
ES2425228T3 (es) * 2005-09-09 2013-10-14 Intervet International B.V. Vacuna contra el PCV-2
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
EP3868400A1 (en) 2005-12-29 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
MX2008012972A (es) 2006-04-10 2009-01-16 Intervet Int Bv Vacuna contra sindrome respiratorio reproductivo porcino atenuado vivo de micoplasma.
CN101420975B (zh) * 2006-04-10 2012-06-27 英特威国际有限公司 抗支原体和prrsv的疫苗
EP2217271B1 (en) 2007-11-06 2016-05-04 Zoetis Services LLC Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
KR101320192B1 (ko) 2008-10-16 2013-10-30 조에티스 엘엘씨 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물
WO2011141443A1 (en) 2010-05-11 2011-11-17 Intervet International B.V. Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
BR112013004594B1 (pt) 2010-08-27 2020-07-28 Intervet International B. V. método para a determinação de um conteúdo de antígeno
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
BR112014022067B1 (pt) 2012-03-07 2022-05-31 Ceva Sante Animale Composição compreendendo antígeno e lipopolissacarídeo
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DJORDJEVIC S. et al., AUSTRALIAN VETERINARY JOURNAL, 1 July 1997, vol. 75, no. 7, pages 504-511. *

Also Published As

Publication number Publication date
MX354773B (es) 2018-03-20
KR101808903B1 (ko) 2017-12-13
CO7160027A2 (es) 2015-01-15
AU2013243540A1 (en) 2014-10-09
RU2644256C2 (ru) 2018-02-08
JP6271504B2 (ja) 2018-01-31
HRP20140956A2 (hr) 2015-04-24
EP3508217A1 (en) 2019-07-10
US20150284678A1 (en) 2015-10-08
CA2869601C (en) 2018-06-12
CY1121578T1 (el) 2020-05-29
TW201345548A (zh) 2013-11-16
MX336502B (es) 2016-01-21
JP2015512450A (ja) 2015-04-27
CA2869601A1 (en) 2013-10-10
CL2014002676A1 (es) 2014-12-12
GT201400212A (es) 2015-09-23
ZA201407133B (en) 2017-02-22
TR201905176T4 (tr) 2019-05-21
NI201400118A (es) 2015-03-05
US9125886B2 (en) 2015-09-08
WO2013152086A1 (en) 2013-10-10
RS58480B1 (sr) 2019-04-30
PH12014502252A1 (en) 2014-12-15
AU2013243540B2 (en) 2017-10-19
KR20150002748A (ko) 2015-01-07
CN104271153A (zh) 2015-01-07
MX2014012016A (es) 2014-11-10
TWI504406B (zh) 2015-10-21
AR090614A1 (es) 2014-11-26
EP2833909B1 (en) 2019-02-06
HRP20190466T1 (hr) 2019-05-03
MY168549A (en) 2018-11-12
US20130266603A1 (en) 2013-10-10
ES2719483T3 (es) 2019-07-10
CR20140438A (es) 2014-11-12
BR112014024775B1 (pt) 2021-06-08
DK2833909T3 (en) 2019-04-01
PH12014502252B1 (en) 2014-12-15
HK1207283A1 (en) 2016-01-29
PT2833909T (pt) 2019-05-13
SI2833909T1 (sl) 2019-05-31
US9650601B2 (en) 2017-05-16
EP2833909A1 (en) 2015-02-11
PL2833909T3 (pl) 2019-07-31
UA114504C2 (uk) 2017-06-26
BR112014024775A2 (pt) 2017-07-11
HUE042405T2 (hu) 2019-06-28
RU2014140108A (ru) 2016-06-10
LT2833909T (lt) 2019-04-10

Similar Documents

Publication Publication Date Title
AU2013243540C1 (en) PCV/Mycoplasma hyopneumoniae/PRRS combination vaccine
US11141472B2 (en) Mycoplasma hyopneumoniae vaccine
US20200338187A1 (en) Pcv/mycoplasma hyopneumoniae vaccine
HK40072009A (en) Mycoplasma hyopneumoniae vaccine
HK40010886A (en) Pcv/mycoplasma hyopneumoniae/prrs combination vaccine
HK40010885A (en) Pcv/mycoplasma hyopneumoniae combination vaccine
HK1207283B (en) Pcv/mycoplasma hyopneumoniae/prrs combination vaccine
HK1206609B (en) Pcv/mycoplasma hyopneumoniae combination vaccine

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ZOETIS SERVICES LLC

Free format text: FORMER APPLICANT(S): ZOETIS LLC

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 NOV 2017

CB Opposition filed

Opponent name: MERIAL LIMITED

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 NOV 2017

ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: (2020) APO 40: DECISION: THE OPPOSITION ON 2013243540 HAS NOT BEEN SUCCESSFUL.THE OPPONENT TO PAY COSTS ON 2013243540.

Opponent name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

Effective date: 20200828

MK16 Application refused